Cloud Contradiction: Despite Security Driving Cloud Adoption, Aptum Study Reveals It’s also the Main Barrier to Cloud Transformation
18.1.2021 17:00:00 EET | Business Wire | Press release
While 91% of organizations were successful in increasing security as a result of adopting cloud services, it remains a top concern for many. This finding comes from part two of the four-part Cloud Impact Study from Aptum, the global hybrid multi-cloud managed service provider. The report, titled The Security and Compliance Barricade , identifies common security, compliance and governance challenges impacting organizations undergoing cloud transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005035/en/
Aptum Cloud Impact Study Pt 2.: The Security and Compliance Barricade (Graphic: Business Wire)
The independent research reveals that more than half of survey respondents (51%) see security as the main driver behind cloud adoption. However, 38% cite security and data protection as the primary barrier to cloud transformation.
Security and compliance play a critical role
Part one of the Cloud Impact Study, Bridging the Cloud Gap , found most survey respondents plan to take a hybridized approach to their cloud infrastructure, with more than half (59%) of respondents saying they will reduce their on-premises infrastructure to some degree and increase public cloud deployments within the next 18-24 months. A further 66% intend to expand their private cloud workloads.
According to data found in today’s report, this expansion and diversification of infrastructure raises security and compliance issues among senior IT professionals, including:
- Control and governance (82%)
- Visibility through a single portal (81%)
- Ability to meet requirements of compliancy audits (80%)
“Organizations are enjoying a newfound agility as they embrace hybrid cloud solutions, but scattered workloads present a security concern," explains Craig Tavares, Global Head of Cloud at Aptum. “A cloud environment is only as secure as the polices and controls an organization has in place, which is why they need to be built into the formation of any cloud strategy. Although no single solution on its own can guarantee 100% security, especially in a multi/hybrid cloud approach, experienced partners can assist organizations in choosing the right combination of security technologies that compliments their workloads no matter where they are hosted and ensure visibility across disparate environments."
“Security teams are tasked with protecting a widening attack surface, often with limited budgets and resources, against bad actors who are employing the same sophisticated techniques as top cybersecurity providers,” said Dan Webb, VP of Partner Sales and Alliances, Alert Logic. “With the ubiquity of cloud and hybrid environments, containerization, and mobile, IoT, and other edge devices, the traditional notion of a perimeter is no more. To be effective, security solutions must enable total visibility across an organization’s IT estate to help organizations quickly identify, prioritize, and respond to all threats that surface.”
Together, Aptum and Alert Logic partner to safeguard business critical data across the infrastructure and application stack, merging security technology, threat intelligence and 24/7 security experts to deliver security outcomes to businesses in an as-a-service model.
The study’s results reinforce the importance of incorporating security into cloud architectures from design through to implementation and transformation. The results call for organizations to take a holistic approach to cloud architectures, with security principles embedded in the design. By doing this, businesses can mitigate threats and minimize risks as they arise to create an environment safer than any on-premise or legacy alternatives.
The full findings of part two of the Cloud Impact Study, The Security and Compliance Barricade, can be found here.
Aptum’s Cloud Impact Study was created from the opinions of 400 senior IT professionals in the US, Canada and UK across industries in financial services, IT, technology, telecommunications, manufacturing, retail, public and commercial sectors. The final two reports will focus on Costs and Budgets and Modernization Opportunities.
For part one of the report, Bridging the Cloud Gap, please visit here.
About Aptum Technologies
Aptum Technologies enables customers to unlock the potential of their data infrastructure to drive tangible business outcomes and maximize the value of their technology investments. Aptum’s Data Center, Cloud, Hosting and Global Network solutions, underpinned with expert Managed and Professional Services, offer genuine choice and adaptability combined with international reach spanning North America, Latin America, Europe and the United Kingdom. Aptum is a portfolio company of Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. For more information, visit www.aptum.com.
Connect with Aptum
Official Blog| LinkedIn | Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005035/en/
Contact information
Media Contact
Tonique Bedeau, Aptum Technologies
media@aptum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
